{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:27:05Z","timestamp":1791412025275,"version":"4.3.3"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2005,9,1]]},"DOI":"10.1038\/nrd1824","type":"journal-article","created":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T18:53:00Z","timestamp":1125600780000},"page":"727-740","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":440,"title":["Opportunities and Challenges in Antiparasitic Drug Discovery"],"prefix":"10.1038","volume":"4","author":[{"given":"Richard","family":"Pink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Annick","family":"Mouri\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Bendig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrd1824_CR1","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/S0140-6736(02)09096-7","volume":"359","author":"P Trouiller","year":"2002","unstructured":"Trouiller, P. et al. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 359, 2188\u20132194 (2002). Review of the history of the discovery and development of drugs for neglected diseases, making it clear that non-market-driven mechanisms are required to stimulate new drug development","journal-title":"Lancet"},{"key":"BFnrd1824_CR2","unstructured":"Global Forum for Health Research. The 10\/90 Report on Health Research, 2003\u20132004 (Global Forum for Health Research, Geneva, 2004)."},{"key":"BFnrd1824_CR3","unstructured":"M\u00e9decins Sans Fronti\u00e8res Access to Essential Medicines Campaign. Fatal Imbalance: The crisis in Research and Development for Drugs for Neglected Diseases (M\u00e9decins Sans Fronti\u00e8res, Geneva, 2001)."},{"key":"BFnrd1824_CR4","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/nrd1230","volume":"2","author":"S Nwaka","year":"2003","unstructured":"Nwaka, S. & Ridley, R. G. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nature Rev. Drug Discov. 2, 919\u2013928 (2003). A clear discussion of the role and importance of public-private partnerships.","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd1824_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nrd1308","volume":"3","author":"HE Kettler","year":"2004","unstructured":"Kettler, H. E. & Marjanovic, S. Engaging biotechnology companies in the development of innovative solutions for diseases of poverty. Nature Rev. Drug Discov. 3, 171\u2013176 (2004).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd1824_CR6","unstructured":"Medicines for Malaria Venture. Annual Report 2002 [online], <http:\/\/www.mmv.org\/filesupld\/53.pdf> (2003)."},{"issue":"Suppl.","key":"BFnrd1824_CR7","doi-asserted-by":"publisher","first-page":"S137","DOI":"10.1038\/nm1153","volume":"10","author":"RG Ridley","year":"2004","unstructured":"Ridley, R. G. Research on infectious diseases requires better coordination. Nature Med. 10 (Suppl.), S137\u2013S140 (2004).","journal-title":"Nature Med."},{"key":"BFnrd1824_CR8","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1242\/jeb.00589","volume":"206","author":"PJ Rosenthal","year":"2003","unstructured":"Rosenthal, P. J. Antimalarial drug discovery: old and new approaches. J. Exp. Biol. 206, 3735\u20133744 (2003).","journal-title":"J. Exp. Biol."},{"key":"BFnrd1824_CR9","unstructured":"Barry, C. E. III & Duncan K. Tuberculosis \u2014 strategies towards anti-infectives for a chronic disease. Drug Discov. Today: Ther. Strat. (in the press)."},{"key":"BFnrd1824_CR10","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1136\/bmj.329.7475.1156","volume":"329","author":"ML Willcox","year":"2004","unstructured":"Willcox, M. L. & Bodeker, G. Traditional herbal medicines for malaria. BMJ 329, 1156\u20131159 (2004).","journal-title":"BMJ"},{"key":"BFnrd1824_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nbt0304-263","volume":"22","author":"P Basu","year":"2004","unstructured":"Basu, P. Trading on traditional medicines. Nature Biotechnol. 22, 263\u2013265 (2004).","journal-title":"Nature Biotechnol."},{"key":"BFnrd1824_CR12","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1046\/j.1365-3156.2002.00933.x","volume":"7","author":"B Mpia","year":"2002","unstructured":"Mpia, B. & Pepin, J. Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis. Trop. Med. Int. Health 7, 775\u2013779 (2002).","journal-title":"Trop. Med. Int. Health"},{"key":"BFnrd1824_CR13","unstructured":"TDR. TDR Sixteenth Programme Report: Progress 2001\u20132002 [online], < http:\/\/www.who.int\/tdr\/publications\/publications\/pr16.htm> (2003)."},{"key":"BFnrd1824_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0140-6736(04)16680-4","volume":"364","author":"PG Kremsner","year":"2004","unstructured":"Kremsner, P. G. & Krishna, S. Antimalarial combinations. Lancet 364, 285\u2013294 (2004). Thoughtful analysis of the current combination therapies used in the treatment\/prophylaxis of malaria.","journal-title":"Lancet"},{"key":"#cr-split#-BFnrd1824_CR15.1","unstructured":"Medicines for Malaria Venture. Annual Report 2003 [online], <http:\/\/www.mmv.org\/FilesUpld\/184.pdf&gt"},{"key":"#cr-split#-BFnrd1824_CR15.2","unstructured":"(2004). Review of the MMV portfolio of projects. A more up-to-date Annual Report for 2004 is now available. Much information on anti-parasite drug development projects is also available from the MMV, DNDi and IOWH web sites cited in Table 5."},{"key":"BFnrd1824_CR16","first-page":"1086","volume":"6","author":"C Yeates","year":"2003","unstructured":"Yeates, C. DB-289 Immtech International. IDrugs 6, 1086\u20131093 (2003).","journal-title":"IDrugs"},{"key":"BFnrd1824_CR17","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.pt.2003.09.001","volume":"19","author":"JA Urbina","year":"2003","unstructured":"Urbina, J. A. & Docampo, R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol. 19, 495\u2013501 (2003).","journal-title":"Trends Parasitol."},{"key":"BFnrd1824_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nsb921","volume":"10","author":"J Yuvaniyama","year":"2003","unstructured":"Yuvaniyama, J. et al. Insights into antifolate resistance from malarial DHFR-TS structures. Nature Struct. Biol. 10, 357\u2013365 (2003).","journal-title":"Nature Struct. Biol."},{"key":"BFnrd1824_CR19","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1021\/jm030796n","volume":"46","author":"PM O'Neill","year":"2003","unstructured":"O'Neill, P. M. et al. Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials. J. Med. Chem. 46, 4933\u20134945 (2003).","journal-title":"J. Med. Chem."},{"key":"BFnrd1824_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1021\/mp0500061","volume":"2","author":"C Biot","year":"2005","unstructured":"Biot, C. et al. Insights into the mechanism of action of ferroquine. Relationship between physicochemical properties and antiplasmodial activity. Mol. Pharm. 2, 185\u2013193 (2005). An example of how successful veterinary drugs have been identified that have the potential to be important drugs for the treatment of human diseases.","journal-title":"Mol. Pharm."},{"key":"BFnrd1824_CR21","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1177\/0091270003257456","volume":"43","author":"MM Cotreau","year":"2003","unstructured":"Cotreau, M. M. et al. The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans. J. Clin. Pharmacol. 43, 1108\u20131115 (2003).","journal-title":"J. Clin. Pharmacol."},{"key":"BFnrd1824_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.tmaid.2004.03.002","volume":"2","author":"S Nwaka","year":"2004","unstructured":"Nwaka, S., Riopel, L., Ubben, D. & Craft, J. C. Medicines for Malaria Venture new developments in antimalarials. Travel Med. and Inf. Disease 2, 161\u2013170 (2004).","journal-title":"Travel Med. and Inf. Disease"},{"key":"BFnrd1824_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0065-308X(01)50032-9","volume":"50","author":"S Tagboto","year":"2001","unstructured":"Tagboto, S. & Townson, S. Antiparasitic properties of medicinal plants and other naturally occurring products. Adv. Parasitol. 50, 199\u2013295 (2001).","journal-title":"Adv. Parasitol."},{"key":"BFnrd1824_CR24","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1126\/science.3887571","volume":"228","author":"DL Klayman","year":"1985","unstructured":"Klayman, D. L. Qinghaosu (artemisinin): an antimalarial drug from China. Science 228, 1049\u20131055 (1985).","journal-title":"Science"},{"key":"BFnrd1824_CR25","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1128\/AAC.44.6.1645-1649.2000","volume":"44","author":"KK Ang","year":"2000","unstructured":"Ang, K. K., Holmes, M. J., Higa, T., Hamann, M. T. & Kara, U. A. In vivo antimalarial activity of the \u03b2-carboline alkaloid manzamine A. Antimicrob. Agents Chemother. 44, 1645\u20131649 (2000).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd1824_CR26","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1016\/S0968-0896(03)00233-5","volume":"11","author":"M Lui","year":"2003","unstructured":"Lui, M., Wilairat, P., Croft, S. L., Tan, L. C. A. & Go, M. L. Structure\u2013activity relationships of antileishmanial and antimalarial chalcones. Bioorg. Med. Chem. 11, 2729\u20132738 (2003).","journal-title":"Bioorg. Med. Chem."},{"key":"BFnrd1824_CR27","doi-asserted-by":"publisher","first-page":"727","DOI":"10.7164\/antibiotics.56.727","volume":"56","author":"K Otoguro","year":"2003","unstructured":"Otoguro, K. et al. In vitro and in vivo antimalarial activities of a non-glycosidic 18-membered macrolide antibiotic, borrelidin, against drug-resistant strains of Plasmodia. J. Antibiot. (Tokyo) 56, 727\u2013729 (2003). An example of one type of computational analysis that may be helpful in deciding which parasite targets are worth pursuing.","journal-title":"J. Antibiot."},{"key":"BFnrd1824_CR28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1128\/AAC.48.1.130-136.2004","volume":"48","author":"L Maes","year":"2004","unstructured":"Maes, L et al. In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral leishmania species. Antimicrob. Agents Chemother. 48, 130\u2013136 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd1824_CR29","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1101\/gr.2050304","volume":"14","author":"I Yeh","year":"2004","unstructured":"Yeh, I., Hanekamp, T., Tsoka, S., Karp, P. D. & Altman, R. B. Computational analysis of Plasmodium falciparum metabolism: organizing genomic information to facilitate drug discovery. Genome Research 14, 917\u2013924 (2004).","journal-title":"Genome Research"},{"key":"BFnrd1824_CR30","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrd892","volume":"1","author":"AL Hopkins","year":"2002","unstructured":"Hopkins, A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727\u2013730 (2002).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd1824_CR31","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.mib.2004.08.013","volume":"7","author":"K Bush","year":"2004","unstructured":"Bush, K., Macielag, M. & Weidner-Wells, M. Taking inventory: antibacterial agents currently at or beyond phase 1. Curr. Opin. Microbiol. 7, 466\u2013476 (2004).","journal-title":"Curr. Opin. Microbiol."},{"key":"BFnrd1824_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1359-6446(04)03285-4","volume":"10","author":"KM Overbye","year":"2005","unstructured":"Overbye, K. M. & Barrett, J. F. Antibiotics: where did we go wrong? Drug Discov. Today 10, 45\u201352 (2005).","journal-title":"Drug Discov. Today"},{"key":"BFnrd1824_CR33","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.mib.2004.08.009","volume":"7","author":"CJ Thomson","year":"2004","unstructured":"Thomson, C. J., Power, E., Ruebsamen-Waigmann, H. & Labischinski, H. Antibacterial research and development in the 21(st) century \u2014 an industry perspective of the challenges. Curr. Opin. Microbiol. 7, 445\u2013450 (2004).","journal-title":"Curr. Opin. Microbiol."},{"key":"BFnrd1824_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S1359-6446(04)03275-1","volume":"10","author":"P Gribbon","year":"2005","unstructured":"Gribbon, P. & Sewing, A. High-throughput drug discovery: what can we expect from HTS? Drug Discov. Today 10, 17\u201322 (2005).","journal-title":"Drug Discov. Today"},{"key":"BFnrd1824_CR35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nrd1086","volume":"2","author":"KH Bleicher","year":"2003","unstructured":"Bleicher, K. H., Bohm, H. J., Muller, K. & Alanine, A. I. Hit and lead generation: beyond high-throughput screening. Nature Rev. Drug Discov. 2, 369\u2013378 (2003).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd1824_CR36","doi-asserted-by":"publisher","first-page":"8721","DOI":"10.1016\/S0021-9258(18)47475-3","volume":"262","author":"MA Phillips","year":"1987","unstructured":"Phillips, M. A., Coffino, P. & Wang, C. C. Cloning and sequencing of the ornithine decarboxylase gene from Trypanosoma brucei: implications for enzyme turnover and selective difluoromethylornithine inhibition. J. Biol. Chem. 262, 8721\u20138727 (1987). Useful modus operandi for how genomics data can be used in the selection of molecular targets for helminth drug discovery.","journal-title":"J. Biol. Chem."},{"key":"BFnrd1824_CR37","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nrd1692","volume":"4","author":"AK Jones","year":"2005","unstructured":"Jones, A. K., Buckingham, S. D. & Sattelle, D. B. Chemistry-to-gene screens in Caenorhabditis elegans. Nature Rev. Drug Discov. 4, 321\u2013330 (2005). A recommended approach and set of procedures in the discovery path to new anti-malarial drugs, much of which is applicable to the discovery of other anti-parasitic drugs.","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd1824_CR38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.pt.2004.12.003","volume":"21","author":"CA Behm","year":"2005","unstructured":"Behm, C. A., Bendig, M. M., McCarter, J. P. & Sluder, A. E. RNAi-based discovery and validation of new drug targets in filarial nematodes. Trends Parasitol. 21, 97\u2013100 (2005).","journal-title":"Trends Parasitol."},{"key":"BFnrd1824_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0166-6851(01)00438-8","volume":"120","author":"M Sajid","year":"2002","unstructured":"Sajid, M. & McKerrow, J. H. Cysteine proteases of parasitic organisms. Mol. Biochem. Parasitol. 120, 1\u201321 (2002).","journal-title":"Mol. Biochem. Parasitol."},{"key":"BFnrd1824_CR40","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.2174\/0929867043364469","volume":"11","author":"CC Musonda","year":"2004","unstructured":"Musonda, C. C. & Chibale, K. Application of combinatorial and parallel synthesis methodologies to antiparasite drug discovery. Curr. Med. Chem. 11, 2519\u20132533 (2004). Excellent example of a successful lead optimization program made all the more noteworthy by the fact that the lead compounds are 1,2,4 - trioxolanes (ozonides), a chemical class which would not normally be considered drug-like.","journal-title":"Curr. Med. Chem."},{"key":"BFnrd1824_CR41","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrd1416","volume":"3","author":"DA Fidock","year":"2004","unstructured":"Fidock, D. A., Rosenthal, P. J., Croft, S. L., Brun, R. & Nwaka, S. Antimalarial drug discovery: efficacy models for compound screening. Nature Rev. Drug Discov. 3, 509\u2013520 (2004).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd1824_CR42","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1128\/AAC.47.12.3810-3814.2003","volume":"47","author":"BJ Lee","year":"2003","unstructured":"Lee, B. J. et al. Antimalarial activities of novel synthetic cysteine protease inhibitors. Antimicrob. Agents Chemother. 47, 3810\u20133814 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd1824_CR43","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1179\/000349802125001744","volume":"96","author":"W Peters","year":"2002","unstructured":"Peters, W., Fleck, S. L, Robinson, B. L., Stewart, L. B & Jefford, C. W. The chemotherapy of rodent malaria. LX. The importance of formulation in evaluating the blood schizontocidal activity of some endoperoxide antimalarials. Ann. Trop. Med. Parasitol. 96, 559\u2013573 (2002).","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"BFnrd1824_CR44","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/nature02779","volume":"430","author":"JL Vennerstrom","year":"2004","unstructured":"Vennerstrom, J. L. et al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430, 900\u2013904 (2004).","journal-title":"Nature"},{"key":"BFnrd1824_CR45","unstructured":"Bendig, M. Graduate of the TDR 'malperox' programme reaches the clinics. TDRnews 73, Oct (2004)."},{"key":"BFnrd1824_CR46","first-page":"713","volume":"79","author":"R Widdus","year":"2001","unstructured":"Widdus, R. Public\u2013private partnerships for health: their main targets, their diversity, and their future directions. Bull. World Health Organ. 79, 713\u2013720 (2001).","journal-title":"Bull. World Health Organ."},{"key":"BFnrd1824_CR47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1478-4505-2-5","volume":"2","author":"S Nishtar","year":"2004","unstructured":"Nishtar, S. Public\u2013private 'partnerships' in health \u2014 a global call to action. Health Res. Policy Syst. 2, 5 (2004). A wide-ranging overview with emphasis on the need for effective coordination of research and control activities.","journal-title":"Health Res. Policy Syst."},{"key":"BFnrd1824_CR48","first-page":"735","volume":"79","author":"D Webber","year":"2001","unstructured":"Webber, D. & Kremer, M. Perspectives on stimulating industrial research and development for neglected infectious diseases. Bull. World Health Organ. 79, 735\u2013741 (2001).","journal-title":"Bull. World Health Organ."},{"key":"BFnrd1824_CR49","first-page":"P06","volume":"19","author":"J Horton","year":"2003","unstructured":"Horton, J. Drug development for tropical diseases \u2014 present situation, future perspectives. Trends Parasitol. 19, P06 (2003).","journal-title":"Trends Parasitol."},{"key":"BFnrd1824_CR50","doi-asserted-by":"crossref","unstructured":"Editorial. Africa 2005. Nature 433, 669 (2005).","DOI":"10.1038\/433669a"},{"issue":"2 Suppl.","key":"BFnrd1824_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4269\/ajtmh.2004.71.2_suppl.0700001","volume":"71","author":"JG Breman","year":"2004","unstructured":"Breman, J. G., Alilio, M. S. & Mills, A. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am. J. Trop. Med. Hyg. 71 (2 Suppl.), 1\u201315 (2004).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"BFnrd1824_CR52","unstructured":"World Health Organization. The World Health Report 2004 [online], <http:\/\/www.who.int\/whr\/en\/> (2004)."},{"issue":"Supp. 1","key":"BFnrd1824_CR53","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1007\/s00436-002-0766-5","volume":"90","author":"C Burri","year":"2003","unstructured":"Burri, C. & Brun, R. Eflornithine for the treatment of human African trypanosomiasis. Parasitol. Res. 90 (Supp. 1, S49\u2013S52 (2003).","journal-title":"Parasitol. Res."},{"key":"BFnrd1824_CR54","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1128\/AAC.47.2.735-738.2003","volume":"47","author":"B Lell","year":"2003","unstructured":"Lell, B. et al. Fosmidomycin, a novel chemotherapeutic agent for malaria. Antimicrob. Agents Chemother. 47, 735\u2013738 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd1824_CR55","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1056\/NEJM199912093412403","volume":"341","author":"T Jha","year":"1999","unstructured":"Jha, T. et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N. Engl. J. Med. 341, 1795\u20131800 (1999).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd1824_CR56","unstructured":"Medicines for Malaria Venture. Annual Report 2003 [online], <http:\/\/www.mmv.org\/FilesUpld\/184.pdf> (2003)."},{"key":"BFnrd1824_CR57","doi-asserted-by":"publisher","first-page":"13944","DOI":"10.1073\/pnas.94.25.13944","volume":"94","author":"T Triglia","year":"1997","unstructured":"Triglia, T., Menting, J. G., Wilson, C. & Cowman, A. F. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc. Natl Acad. Sci. USA 94, 13944\u201313949 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd1824_CR58","first-page":"427","volume":"17","author":"AT Hudson","year":"1991","unstructured":"Hudson, A. T. et al. 566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs Exp. Clin. Res. 17, 427\u2013435 (1991).","journal-title":"Drugs Exp. Clin. Res."},{"key":"BFnrd1824_CR59","unstructured":"Looareesuwan, S., Chulay, J. D., Canfield, C. J. & Hutchinson, D. B. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria."},{"key":"BFnrd1824_CR60","doi-asserted-by":"crossref","unstructured":"Malarone Clinical Trials Study Group. Am. J. Trop. Med. Hyg. 60, 533\u2013541 (1999).","DOI":"10.4269\/ajtmh.1999.60.533"},{"key":"BFnrd1824_CR61","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/0006-2952(92)90213-3","volume":"43","author":"M Fry","year":"1992","unstructured":"Fry, M. & Pudney, M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem. Pharmacol. 43, 1545\u20131553 (1992).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrd1824_CR62","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1126\/science.285.5433.1573","volume":"285","author":"H Jomaa","year":"1999","unstructured":"Jomaa, H. et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science 285, 1573\u20131576 (1999).","journal-title":"Science"},{"key":"BFnrd1824_CR63","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1086\/381785","volume":"189","author":"S Borrmann","year":"2004","unstructured":"Borrmann, S. et al. Fosmidomycin\u2013clindamycin in Plasmodium falciparum infections in African children. J. Infect. Dis. 189, 901\u2013908 (2004).","journal-title":"J. Infect. Dis."},{"key":"BFnrd1824_CR64","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0001-706X(93)90089-T","volume":"54","author":"FA Kuzoe","year":"1993","unstructured":"Kuzoe, F. A. Current situation of African trypanosomiasis. Acta Trop. 54, 153\u2013162 (1993).","journal-title":"Acta Trop."},{"key":"BFnrd1824_CR65","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1517\/13543776.13.5.661","volume":"13","author":"JA, Urbina","year":"2003","unstructured":"Urbina J. A., New chemotherapeutic approaches for the treatment of Chagas disease (American trypanosomiasis). Expert Opin. Ther. Patents 13, 661\u2013669 (2003).","journal-title":"Expert Opin. Ther. Patents"},{"key":"BFnrd1824_CR66","doi-asserted-by":"publisher","first-page":"15149","DOI":"10.1073\/pnas.2535442100","volume":"100","author":"F Buckner","year":"2003","unstructured":"Buckner, F. et al. A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc. Natl Acad. Sci. USA 100, 15149\u201315153 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd1824_CR67","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1021\/jm0002578","volume":"44","author":"MB Martin","year":"2001","unstructured":"Martin, M. B. et al. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii and Plasmodium falciparum: a potential route to chemotherapy. J. Med. Chem. 44, 909\u2013916 (2001).","journal-title":"J. Med. Chem."},{"key":"BFnrd1824_CR68","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S1090-0233(05)80005-X","volume":"154","author":"RJ Martin","year":"1997","unstructured":"Martin, R. J. Modes of action of anthelmintic drugs. Vet. J. 154, 11\u201334 (1997).","journal-title":"Vet. J."},{"key":"BFnrd1824_CR69","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/0169-4758(90)90227-U","volume":"6","author":"E Lacey","year":"1990","unstructured":"Lacey, E. Mode of action of benzimidazoles. Parasitol. Today, 6, 112\u2013115 (1990).","journal-title":"Parasitol. Today"},{"key":"BFnrd1824_CR70","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/nrmicro1048","volume":"2","author":"S Omura","year":"2004","unstructured":"Omura, S. & Crump, A. The life and times of ivermectin \u2014 a success story. Nature Rev. Microbiol. 2, 984\u2013989 (2004).","journal-title":"Nature Rev. Microbiol."},{"issue":"Suppl.","key":"BFnrd1824_CR71","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.1017\/S0031182000077970","volume":"113","author":"DF Cully","year":"1996","unstructured":"Cully, D. F., Wilkinson, H., Vassilatis, D. K., Etter, A. & Arena, J. P. Molecular biology and electrophysiology of glutamate-gated chloride channels of invertebrates. Parasitology 113 (Suppl.) S191\u2013S200 (1996).","journal-title":"Parasitology"},{"key":"BFnrd1824_CR72","doi-asserted-by":"publisher","first-page":"21847","DOI":"10.1074\/jbc.M501100200","volume":"280","author":"J Baldwin","year":"2005","unstructured":"Baldwin, J. et al. High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J. Biol. Chem. 280, 21847\u201321853 (2005).","journal-title":"J. Biol. Chem."},{"key":"BFnrd1824_CR73","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1073\/pnas.102679799","volume":"99","author":"LE Kemp","year":"2002","unstructured":"Kemp, L. E., Bond, C. S. & Hunter, W. N. Structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase: An essential enzyme for isoprenoid biosynthesis and target for antimicrobial drug development. Proc. Natl Acad. Sci. USA 99, 6591\u20136596 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd1824_CR74","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.ijpara.2004.10.003","volume":"34","author":"PJ Rosenthal","year":"2004","unstructured":"Rosenthal, P. J. Cysteine proteases of malaria parasites. Int. J. Parasitol. 34, 1489\u20131499 (2004).","journal-title":"Int. J. Parasitol."},{"key":"BFnrd1824_CR75","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0166-6851(02)00282-7","volume":"126","author":"MH Gelb","year":"2003","unstructured":"Gelb, M. H. et al. Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol. Biochem. Parasitol. 126, 155\u2013163 (2003).","journal-title":"Mol. Biochem. Parasitol."},{"key":"BFnrd1824_CR76","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1021\/jm030236o","volume":"47","author":"J Ohkanda","year":"2004","unstructured":"Ohkanda, J. et al. Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents. J. Med. Chem. 47, 432\u2013445 (2004).","journal-title":"J. Med. Chem."},{"key":"BFnrd1824_CR77","doi-asserted-by":"publisher","first-page":"12352","DOI":"10.1073\/pnas.95.21.12352","volume":"95","author":"RF Waller","year":"1998","unstructured":"Waller, R. F. et al. Nuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum. Proc. Natl Acad. Sci. USA 95, 12352\u201312357 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd1824_CR78","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1126\/science.288.5463.140","volume":"288","author":"YS Morita","year":"2000","unstructured":"Morita, Y. S., Paul, K. S. & Englund, P. T. Specialised fatty acid synthesis in African trypanosomes: myristate for GPI anchors. Science 288, 140\u2013143 (2000).","journal-title":"Science"},{"key":"BFnrd1824_CR79","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/84612","volume":"7","author":"N Surolia","year":"2001","unstructured":"Surolia, N. & Surolia, A. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nature Med. 7, 167\u2013173 (2001).","journal-title":"Nature Med."},{"key":"BFnrd1824_CR80","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0169-4758(99)01627-0","volume":"16","author":"T Meinnel","year":"2000","unstructured":"Meinnel, T. Peptide deformylase of eukaryotic protists: a target for new antiparasitic agents? Parasitol. Today 16, 165\u2013168 (2000).","journal-title":"Parasitol. Today"},{"key":"BFnrd1824_CR81","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.actatropica.2003.11.003","volume":"89","author":"T Joet","year":"2004","unstructured":"Joet, T. & Krishna, S. The hexose transporter of Plasmodium falciparum is a worthy drug target. Acta Trop. 89, 371\u2013374 (2004).","journal-title":"Acta Trop."},{"key":"BFnrd1824_CR82","doi-asserted-by":"publisher","first-page":"39925","DOI":"10.1074\/jbc.M405635200","volume":"279","author":"S Wyllie","year":"2004","unstructured":"Wyllie, S., Cunningham, M. L. & Fairlamb, A. H. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J. Biol. Chem. 279, 39925\u201339932 (2004).","journal-title":"J. Biol. Chem."},{"key":"BFnrd1824_CR83","doi-asserted-by":"publisher","first-page":"29493","DOI":"10.1074\/jbc.M403187200","volume":"279","author":"A Saravanamuthu","year":"2004","unstructured":"Saravanamuthu, A. et al. Two interacting binding sites for quinacrine derivatives in the active site of trypanothione reductase: a template for drug design. J. Biol. Chem. 279, 29493\u201329500 (2004).","journal-title":"J. Biol. Chem."},{"key":"BFnrd1824_CR84","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0378-1119(00)00069-X","volume":"246","author":"CA Daubenberger","year":"2000","unstructured":"Daubenberger, C. A. et al. Identification and recombinant expression of glyceraldehyde-3-phosphate dehydrogenase of Plasmodium falciparum. Gene 246, 255\u2013264 (2000).","journal-title":"Gene"},{"key":"BFnrd1824_CR85","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0166-6851(03)00080-X","volume":"129","author":"M Kron","year":"2003","unstructured":"Kron, M., Petridis, M., Milev, Y., Leykam, J. & Hartlein, M. Expression, localization and alternative function of cytoplasmic asparaginyl-tRNA synthetase in Brugia malayi. Mol. Biochem. Parasitol. 129, 33\u201339 (2003).","journal-title":"Mol. Biochem. Parasitol."},{"key":"BFnrd1824_CR86","doi-asserted-by":"publisher","first-page":"31429","DOI":"10.1074\/jbc.M402433200","volume":"279","author":"A Cameron","year":"2004","unstructured":"Cameron, A. et al. Identification and activity of a series of azole-based compounds with lactate dehydrogenase-directed anti-malarial activity. J. Biol. Chem. 279, 31429\u201331439 (2004).","journal-title":"J. Biol. Chem."},{"key":"BFnrd1824_CR87","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1111\/j.1432-1033.2004.04281.x","volume":"271","author":"AK Tripathi","year":"2004","unstructured":"Tripathi, A. K. et al. An \u03b1-proteobacterial type malate dehydrogenase may complement LDH function in Plasmodium falciparum. Cloning and biochemical characterization of the enzyme. Eur. J. Biochem. 271, 3488\u20133502 (2004).","journal-title":"Eur. J. Biochem."},{"key":"BFnrd1824_CR88","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2174\/1389450003349461","volume":"1","author":"MJ Blackman","year":"2000","unstructured":"Blackman, M. J. Proteases involved in erythrocyte invasion by the malaria parasite: function and potential as chemotherapeutic targets. Curr. Drug Targets 1, 59\u201383 (2000).","journal-title":"Curr. Drug Targets"},{"key":"BFnrd1824_CR89","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0020-7519(02)00186-8","volume":"32","author":"C Doerig","year":"2002","unstructured":"Doerig, C., Endicott, J. & Chakrabarti, D. Cyclin-dependent kinase homologues of Plasmodium falciparum. Int. J. Parasitol. 32, 1575\u20131585 (2002).","journal-title":"Int. J. Parasitol."},{"key":"BFnrd1824_CR90","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2174\/1386207053328183","volume":"8","author":"SM Keenan","year":"2005","unstructured":"Keenan, S. M., Geyer, J. A., Welsh, W. J., Prigge, S. T. & Waters, N. C. Rational inhibitor design and iterative screening in the identification of selective plasmodial cyclin-dependent kinase inhibitors. Comb. Chem. Highthroughput Screen. 8, 27\u201338 (2005).","journal-title":"Comb. Chem. Highthroughput Screen."},{"key":"BFnrd1824_CR91","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.molbiopara.2004.04.012","volume":"137","author":"W Kasekarn","year":"2004","unstructured":"Kasekarn, W., Sirawaraporn, R., Chahomchuen, T., Cowman, A. F. & Sirawaraporn, W. Molecular characterization of bifunctional hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase from Plasmodium falciparum. Mol. Biochem. Parasitol. 137, 43\u201353 (2004).","journal-title":"Mol. Biochem. Parasitol."},{"key":"BFnrd1824_CR92","volume-title":"Burger's Medicinal Chemistry and Drug Discovery","author":"DS Fries","year":"2003","unstructured":"Fries, D. S. & Fairlamb, A. H. in Burger's Medicinal Chemistry and Drug Discovery Sixth Edn Vol. 5: Chemotherapeutic Agents (ed. Abraham, D. J.) Ch. 15 (J. Wiley & Sons, Chichester, 2003)."},{"key":"BFnrd1824_CR93","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.resmic.2004.01.001","volume":"155","author":"L Fumarola","year":"2004","unstructured":"Fumarola, L., Spinelli, R. & Brandonisio, O. In vitro assays for evaluation of drug activity against Leishmania spp. Res. Microbiol. 155, 224\u2013230 (2004).","journal-title":"Res. Microbiol."},{"key":"BFnrd1824_CR94","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1128\/AAC.48.8.2937-2950.2004","volume":"48","author":"SO Lorente","year":"2004","unstructured":"Lorente, S. O. et al. Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis. Antimicrob. Agents Chemother. 48, 2937\u20132950 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd1824_CR95","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0001-706X(97)00079-X","volume":"68","author":"B Raz","year":"1997","unstructured":"Raz, B., Iten, M., Grether-Buhler, Y., Kaminsky, R. & Brun, R. The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Acta Trop. 68, 139\u2013147 (1997).","journal-title":"Acta Trop."},{"key":"BFnrd1824_CR96","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1021\/jm030604o","volume":"47","author":"JH Ansede","year":"2004","unstructured":"Ansede, J. H. et al. O-alkoxyamidine prodrugs of furamidine: in vitro transport and microsomal metabolism as indicators of in vivo efficacy in a mouse model of Trypanosoma brucei rhodesiense infection. J. Med. Chem. 47, 4335\u20134338 (2004).","journal-title":"J. Med. Chem."},{"key":"BFnrd1824_CR97","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4269\/ajtmh.1999.61.193","volume":"61","author":"V Yardley","year":"1999","unstructured":"Yardley, V. & Croft, S. L. In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infections. Am. J. Trop. Med. Hyg. 61, 193\u2013197 (1999).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"BFnrd1824_CR98","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0022-1759(98)00155-0","volume":"220","author":"W Yan","year":"1998","unstructured":"Yan, W. & Moreno, S. N. J. J. Immunol. Methods 220, 123\u2013128 (1998).","journal-title":"J. Immunol. Methods"},{"key":"BFnrd1824_CR99","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0924-8579(02)00274-1","volume":"21","author":"JA Urbina","year":"2003","unstructured":"Urbina, J. A. et al. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int. J. Antimicrob. Agents 21, 39\u201348 (2003).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"BFnrd1824_CR100","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1590\/S0074-02762002000700002","volume":"97","author":"AW Cheever","year":"2002","unstructured":"Cheever, A. W., Lenzi, J. A., Lenzi, H. L. & Andrade, Z. A. Experimental models of Schistosoma mansoni infection. Mem. Inst. Oswaldo Cruz 97, 917\u2013940 (2002).","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"BFnrd1824_CR101","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0020-7519(01)00246-6","volume":"31","author":"YS Liang","year":"2001","unstructured":"Liang, Y. S., Coles, G. C., Doenhoff, M. J. & Southgate V. R. In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel. Int. J. Parasitol. 31, 1227\u20131235 (2001).","journal-title":"Int. J. Parasitol."},{"key":"BFnrd1824_CR102","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.ijpara.2004.05.001","volume":"34","author":"D Cioli","year":"2004","unstructured":"Cioli, D. et al. Determination of ED50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates. Int. J. Parasitol. 34, 979\u2013987 (2004).","journal-title":"Int. J. Parasitol."},{"key":"BFnrd1824_CR103","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0035-9203(02)90110-0","volume":"96","author":"J Utzinger","year":"2002","unstructured":"Utzinger, J., Chollet, J., Tu, Z., Xiao, S. & Tanner, M. Comparative study of the effects of artemether and artesunate on juvenile and adult Schistosoma mansoni in experimentally infected mice. Trans. R. Soc. Trop. Med. Hyg. 96, 318\u2013323 (2002).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"BFnrd1824_CR104","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1258\/0023677011911570","volume":"35","author":"IO Farah","year":"2001","unstructured":"Farah, I. O., Kariuki, T. M., King, C. L. & Hau, J. An overview of animal models in experimental schistosomiasis and refinements in the use of non-human primates. Lab. Anim. 35, 205\u2013212 (2001).","journal-title":"Lab. Anim."},{"key":"BFnrd1824_CR105","first-page":"475","volume":"39","author":"S Townson","year":"1988","unstructured":"Townson, S. The development of a laboratory model for onchocerciasis using Onchocerca gutturosa: in vitro culture, collagenase effects, drug studies and cryopreservation. Trop. Med. Parasitol. 39, 475\u2013479 (1988).","journal-title":"Trop. Med. Parasitol."},{"key":"BFnrd1824_CR106","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2307\/3280031","volume":"63","author":"RR Suswillo","year":"1977","unstructured":"Suswillo, R. R. and Denham, D. A. A new system for testing for filaricidal activity using transplanted adult Brugia in the jird. J. Parasitol. 63, 591\u2013592 (1977).","journal-title":"J. Parasitol."},{"key":"BFnrd1824_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0022149X00011123","volume":"62","author":"JP Court","year":"1988","unstructured":"Court, J. P., Stables, J. N., Lees, G. M., Martin-Short, M. R. & Rankin, R. Dipetalonema viteae and Brugia pahangi transplant infections in gerbils for use in antifilarial screening. J. Helminthol. 62, 1\u20139 (1988).","journal-title":"J. Helminthol."},{"issue":"Suppl.","key":"BFnrd1824_CR108","first-page":"444","volume":"61","author":"JW McCall","year":"1999","unstructured":"McCall, J. W., Dzimianski, M. T., Supakorndej, P. & Jun, J. J. The antifilarial activity of moxidectin against patent infections of Brugia pahangi in dogs. Am. J. Trop. Med. Hygiene 61 (Suppl.), 444 (1999).","journal-title":"Am. J. Trop. Med. Hygiene"},{"key":"BFnrd1824_CR109","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1017\/S0022149X00011494","volume":"62","author":"S Townson","year":"1988","unstructured":"Townson, S., Dobinson, A., Connelly, C. & Muller, R. Chemotherapy of Onchocerca lienalis microfilariae in mice: a model for the evaluation of novel compounds for the treatment of onchocerciasis. J. Helminthol. 62, 181\u2013194 (1988).","journal-title":"J. Helminthol."},{"key":"BFnrd1824_CR110","first-page":"285","volume":"59","author":"G Strote","year":"1990","unstructured":"Strote, G., Weiland, S., Darge, K. & Comley, J. C. W. In vitro assessment of the activity of anthelmintic compounds on adults of Onchocerca volvulus. Acta Liedensia 59, 285\u2013296 (1990).","journal-title":"Onchocerca volvulus. Acta Liedensia"}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrd1824.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrd1824","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrd1824.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T10:57:18Z","timestamp":1744282638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrd1824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,1]]},"references-count":111,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9,1]]}},"alternative-id":["BFnrd1824"],"URL":"https:\/\/doi.org\/10.1038\/nrd1824","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,1]]},"assertion":[{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}